| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2006 | DE102004063752A1 Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of selected CGRP antagonists to combat menopausal hot flashes |
| 07/13/2006 | DE102004063347A1 Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate Ready gemcitabine and Gemcitabinlösungskonzentrate |
| 07/13/2006 | DE102004063269A1 New 9,10-dihydroxy-1,4-dihydroanthracene-1,4-dione compound is protein kinase D inhibitor useful for tumor suppression, inhibition of tumor angiogenesis and the treatment of cancers |
| 07/13/2006 | DE10013539B4 Lipopolysaccharide aus Escherichia coli, Verfahren zu deren Herstellung und deren Verwendungen Lipopolysaccharides from Escherichia coli, to processes for their preparation and their uses |
| 07/13/2006 | CA2830842A1 Method for producing probiotically derived compounds |
| 07/13/2006 | CA2744999A1 Regimens for intra-articular viscosupplementation |
| 07/13/2006 | CA2605214A1 Benzylamine derivatives as cetp inhibitors |
| 07/13/2006 | CA2594488A1 Novel heteropyrrole analogs acting on cannabinoid receptors |
| 07/13/2006 | CA2594433A1 Compositions comprising the 2s,4r ketoconazole enantiomer for treating diabetes, metabolic syndrome and other conditions |
| 07/13/2006 | CA2594418A1 N-(heteroaryl)-1h-indole-2-carb0xamide derivatives and their use as vanilloid trpv1 receptor ligands |
| 07/13/2006 | CA2594404A1 Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| 07/13/2006 | CA2594388A1 Squaric acid derivatives |
| 07/13/2006 | CA2594347A1 Tricyclic d-opioid modulators |
| 07/13/2006 | CA2594334A1 Rnai modulation of rsv and therapeutic uses thereof |
| 07/13/2006 | CA2594332A1 Nanoparticulate candesartan formulations |
| 07/13/2006 | CA2594260A1 Benzoyl-tetrahydropyridine as glyt-1 inhibitors |
| 07/13/2006 | CA2594255A1 Novel pyridine compounds |
| 07/13/2006 | CA2594187A1 Method for producing probiotically derived compounds |
| 07/13/2006 | CA2594116A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 07/13/2006 | CA2594098A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 07/13/2006 | CA2594097A1 Use of selected cgrp antagonists for controlling menopausal hot flashes |
| 07/13/2006 | CA2594096A1 Use of selected cgrp antagonists in combination with other antimigraine medical substances for the treatment of migraine |
| 07/13/2006 | CA2594091A1 Selected benzofuran derivatives |
| 07/13/2006 | CA2594087A1 Plastic bottle for oxaliplatin solution |
| 07/13/2006 | CA2593982A1 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof |
| 07/13/2006 | CA2593793A1 Compounds and methods for regulating triglyceride levels |
| 07/13/2006 | CA2593768A1 Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity |
| 07/13/2006 | CA2593712A1 Substituted benzimidazoles for treatment of histomoniasis |
| 07/13/2006 | CA2593695A1 Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation |
| 07/13/2006 | CA2593612A1 Cxcr4 antagonists for the treatment of hiv infection |
| 07/13/2006 | CA2593578A1 Cxcr4 antagonists for the treatment of medical disorders |
| 07/13/2006 | CA2593563A1 Taurine synthesis, production and utility as a medicine |
| 07/13/2006 | CA2593562A1 Non-irritating compositions containing zinc salts |
| 07/13/2006 | CA2593545A1 Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
| 07/13/2006 | CA2593523A1 Treatment of drug-resistant proliferative disorders |
| 07/13/2006 | CA2593509A1 Rnai agents for maintenance of stem cells |
| 07/13/2006 | CA2593463A1 [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 07/13/2006 | CA2593453A1 Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 07/13/2006 | CA2593432A1 Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 07/13/2006 | CA2593335A1 The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency |
| 07/13/2006 | CA2593266A1 Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| 07/13/2006 | CA2593209A1 Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms) |
| 07/13/2006 | CA2593165A1 Analgesic conjugates |
| 07/13/2006 | CA2593140A1 Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b) |
| 07/13/2006 | CA2593098A1 Sulfonyl pyrrolidines, method for producing the same and their use as drugs |
| 07/13/2006 | CA2593097A1 Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis |
| 07/13/2006 | CA2593055A1 Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| 07/13/2006 | CA2593044A1 Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
| 07/13/2006 | CA2593019A1 Compositions and methods relating to novel compounds and targets thereof |
| 07/13/2006 | CA2593005A1 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| 07/13/2006 | CA2592978A1 Topical stabilized prostaglandin e compound dosage forms |
| 07/13/2006 | CA2592953A1 Rigidified compounds for modulating heparanase activity |
| 07/13/2006 | CA2592909A1 Imidazole derivatives as enzyme reverse transcriptase modulators |
| 07/13/2006 | CA2592900A1 Nitrogen containing bicyclic compounds and therapeutical use thereof |
| 07/13/2006 | CA2592897A1 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
| 07/13/2006 | CA2592883A1 Treatment of hcv disorders |
| 07/13/2006 | CA2592771A1 Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| 07/13/2006 | CA2592743A1 Disubstituted ureas as kinase inhibitors |
| 07/13/2006 | CA2592575A1 Immune response modifier formulations and methods |
| 07/13/2006 | CA2592552A1 Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms) |
| 07/13/2006 | CA2592543A1 Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis |
| 07/13/2006 | CA2592455A1 Substituted 2-amino-quinazolin-4-cn compounds for use in the treatment of cns disorders, pain, stroke, addiction and epilepsy, their preaparation and use as intermediates |
| 07/13/2006 | CA2592007A1 Triazolophthalazines |
| 07/13/2006 | CA2591991A1 Triazolophthalazines |
| 07/13/2006 | CA2591486A1 (5s) -3-[(s)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as cetp inhibitors |
| 07/13/2006 | CA2590556A1 Process for preparing tolterodine tartrate |
| 07/13/2006 | CA2590555A1 Substantially pure tolterodine tartrate and process for preparing thereof |
| 07/13/2006 | CA2590332A1 Inhibitors of checkpoint kinases |
| 07/13/2006 | CA2590110A1 Kinase modulators and method of use |
| 07/13/2006 | CA2589893A1 Inhibitors of checkpoint kinases |
| 07/13/2006 | CA2589830A1 Ubiquitin ligase inhibitors |
| 07/13/2006 | CA2588627A1 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them |
| 07/13/2006 | CA2588026A1 Methods and compositions for rna interference |
| 07/13/2006 | CA2587919A1 Salts of n-[2-({3r)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidine-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide |
| 07/13/2006 | CA2587263A1 Treatment of conditions caused by calcium abnormalities |
| 07/13/2006 | CA2584425A1 1, 5, 6-substituted-2-oxo-3-cyano-1, 6a-diaza-tetrahydro-fluoranthenes |
| 07/13/2006 | CA2576332A1 Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists |
| 07/13/2006 | CA2574616A1 System and method for producing chemical or biochemical signals |
| 07/13/2006 | CA2565242A1 Bioactive compounds and methods of uses thereof |
| 07/13/2006 | CA2564938A1 Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| 07/13/2006 | CA2563511A1 Therapeutic delivery system comprising a high molecular weight peg-like compound |
| 07/12/2006 | EP1679316A1 Stable vitamin b6 derivative |
| 07/12/2006 | EP1679313A2 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 07/12/2006 | EP1679310A1 Phenylene derivative having tetrazole ring or thiazolidinedione ring |
| 07/12/2006 | EP1679309A1 Antistress drug and medical use thereof |
| 07/12/2006 | EP1679308A1 Novel indazole derivative |
| 07/12/2006 | EP1679305A1 9-Substituted minocycline compounds |
| 07/12/2006 | EP1679301A1 Esters of nonsteroidal anti-inflammatory drugs and methods of their preparation |
| 07/12/2006 | EP1679083A2 Use of metaloporphyrins for treatment of arteriosclerotic lesions |
| 07/12/2006 | EP1679079A1 Plant seed extract composition and process for producing the same |
| 07/12/2006 | EP1679077A1 Mucous membrane bulging humor composition comprising chitosan derivative containing saccharide chain for use in condoscopic surgery |
| 07/12/2006 | EP1679076A1 Compounds useful in the treatment of HIV |
| 07/12/2006 | EP1679075A1 Transdermal preparations and method for relieving side effects in pergolide therapy |
| 07/12/2006 | EP1679074A1 Therapeutic agent for keratoconjunctive disorder |
| 07/12/2006 | EP1679073A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(imino-heterocyclyl)-phenyl-amide derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 07/12/2006 | EP1679072A1 Process for for synthesis of (2S,3aS,7aS)-1-(S)-alanyl-octahydro-1H-indole-2- carboxylic acid derivatives and use in the synthesis of perindopril |
| 07/12/2006 | EP1679071A1 Collagen productin enhancer and production process and use thereof |
| 07/12/2006 | EP1679068A1 Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
| 07/12/2006 | EP1679067A1 Concurrent drugs |
| 07/12/2006 | EP1679064A2 Pharmaceutical compositions containing rapamycin derivatives |